Myriad Genetics specializes in molecular diagnostic testing, offering genetic screening and analysis to help inform medical decisions in cancer, women’s health, and mental health. Its products are ...
SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its first ...
Samraat Raha, President and CEO, emphasized progress in high-growth market segments, citing "fourth quarter revenue of $210 million, coming in above the high end of the preannounced range" and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results